User profiles for Nelson Hamerschlak

Nelson Hamerschlak

maria Flora e Israel Hamerschlak
Verified email at einstein.br
Cited by 7253

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or-intolerant chronic myeloid leukemia in blast crisis

…, P Rousselot, DW Kim, E Ritchie, N Hamerschlak… - Blood, 2007 - ashpublications.org
The prognosis for patients with chronic myeloid leukemia (CML) in myeloid blast crisis (MBC)
or lymphoid blast crisis (LBC) remains poor. Although imatinib can induce responses in a …

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial

…, R Pasquini, N Hamerschlak… - Blood, The Journal …, 2007 - ashpublications.org
Therapeutic options for chronic myelogenous leukemia (CML) resistant to 400 to 600 mg
imatinib are limited. Escalating imatinib doses may overcome resistance. Dasatinib, a …

Dasatinib or high‐dose imatinib for chronic‐phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two‐year follow‐up of a …

…, S Jootar, J Holowiecki, N Hamerschlak… - … Journal of the …, 2009 - Wiley Online Library
BACKGROUND: In patients with chronic‐phase chronic myeloid leukemia (CP‐CML), imatinib
resistance is of increasing importance. Imatinib dose escalation was the main treatment …

Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis

…, GE Georges, F Gualandi, N Hamerschlak… - JAMA …, 2017 - jamanetwork.com
Importance Autologous hematopoietic stem cell transplantation (AHSCT) may be effective in
aggressive forms of multiple sclerosis (MS) that fail to respond to standard therapies. …

[HTML][HTML] BCL-2 as therapeutic target for hematological malignancies

…, JV Pinto Neto, LT Campos, N Hamerschlak - Journal of hematology & …, 2018 - Springer
Disruption of the physiologic balance between cell proliferation and cell death is an
important step of cancer development. Increased resistance to apoptosis is a key oncogenic …

Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study

…, A Keating, Y Khaled, N Hamerschlak… - Blood, The Journal …, 2021 - ashpublications.org
Omidubicel is an ex vivo expanded hematopoietic progenitor cell and nonexpanded myeloid
and lymphoid cell product derived from a single umbilical cord blood unit. We report results …

[HTML][HTML] Randomized phase III study of alisertib or investigator's choice (selected single agent) in patients with relapsed or refractory peripheral T-cell lymphoma

…, A Lennard, M Turgut, N Hamerschlak… - Journal of Clinical …, 2019 - ncbi.nlm.nih.gov
… Horwitz, MD, 14 Anne Lennard, MBBS, 15 Mehmet Turgut, MD, 16 Nelson Hamerschlak,
MD, PhD, 17 Francesco A. d’Amore, MD, 18 Francine Foss, MD, 19 Won-Seog Kim, MD …

[HTML][HTML] Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6 blockade–refractory idiopathic multicentric Castleman disease

…, A Schwarer, FF Jose, N Hamerschlak… - The Journal of …, 2019 - Am Soc Clin Investig
Idiopathic multicentric Castleman disease (iMCD) is a rare hematologic illness of systemic
inflammation and organ dysfunction, with unknown etiology. Although therapies targeting IL-6 …

Cost‐effectiveness of the introduction of specialized oral care with laser therapy in hematopoietic stem cell transplantation

…, L Correa, N Hamerschlak… - Hematological …, 2014 - Wiley Online Library
Oral mucositis (OM) is one of the side effects of hematopoietic stem cell transplantation (HSCT),
resulting in major morbidity. The aim of this study was to determine the cost‐…

[PDF][PDF] Salivary SARS-CoV-2 load reduction with mouthwash use: A randomized pilot clinical trial

…, B Stewart, M Ryan, CM Machado, N Hamerschlak… - Heliyon, 2021 - cell.com
The saliva of patients with COVID-19 has a high SARS-CoV-2 viral load. The risk of spreading
the virus is high, and procedures for viral load reduction in the oral cavity are important. …